Rejuvenate Bio co-founder and CEO Daniel Oliver joined host Devin Thorpe on the Superpowers for Good podcast to discuss how the company is turning aging research into one-time gene therapies, starting with pets. In the July 2026 episode, Oliver explained how a single treatment could address multiple chronic diseases and why affordability is central to the company’s strategy.
Oliver said the data suggest one injection could treat several different diseases, whether the patient is a dog, a cat, or eventually a human.
How Rejuvenate Bio Plans to Make Gene Therapy Affordable
Gene therapies for humans can cost millions of dollars per patient. Oliver said Rejuvenate has reduced manufacturing costs for its animal therapies to roughly $100 per dose, low enough to treat chronic, lifelong conditions. He added that this cost discipline could help make future human treatments accessible beyond the wealthiest patients.
The company’s approach is liver-directed gene therapy that does not edit the genome, designed so the body produces therapeutic proteins after a single administration.
Animal Health Partnerships Support the Strategy
Oliver pointed to early work with several major animal health companies, including Merck Animal Health, which also invested in Rejuvenate. That relationship was formalized in June 2026 with a strategic R&D collaboration alongside a $6 million financing.
Leadership Built on Curiosity and Humility
Asked about his personal superpower, Oliver named curiosity and humility. He said startup founders never arrive with every skill they need, so seeking advice and admitting what they don’t know is essential.
About Rejuvenate Bio
Rejuvenate Bio is a San Diego gene therapy company spun out of George Church’s lab at Harvard Medical School. Jetstream Venture Fund invested in the company in June 2026.
Frequently Asked Questions
Who leads Rejuvenate Bio?
Daniel Oliver is co-founder and CEO of Rejuvenate Bio. A graduate of Caltech and Harvard Business School, he previously co-founded Voxel8, a 3D printing company acquired by Kornit Digital, and founded Rejuvenate with Chief Scientific Officer Noah Davidsohn.
How much does Rejuvenate Bio’s animal gene therapy cost to make?
On the Superpowers for Good podcast, CEO Daniel Oliver said Rejuvenate Bio has reduced manufacturing costs for its animal gene therapies to about $100 per dose, low enough to treat chronic, lifelong diseases in companion animals.
Read the Original Article: Rejuvenate Bio’s Breakthrough: Extending Healthy Lives for Pets and Humans